Across TCGA pan-cancer cohorts, EOLA2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EOLA2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher EOLA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EOLA2 expression acts as an unfavorable survival marker.

BRCA and SCLC are the cancer types where EOLA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.657	0.913	.002	22	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: EOLA2 tumor-vs-normal RNA expression · all EOLA2 data types